产品分类

Product category

首页>产品中心>>CAR T-Cell Therapy Cell Lines>79854Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transm...

Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transm...

产品型号:79854

更新时间:2024-11-26

  • 详细介绍
  • 品牌BPS Bioscience
Purchase
Description

Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transmembrane Motif) is a stable cell line expressing an anti-CD19 CAR negative control and an NFAT-dependent luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without the intracellular signaling domains. The reporter cell line has been validated for anti-CD19 expression by flow cytometry, and in co-culture with target cells, such as CD19/CHO recombinant cell line the luciferase reporter gene was not activated. Anti-CD19 CAR Negative Control Jurkat/NFAT (Luciferase) Reporter Cell Line was generated by the transduction of NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) with anti-CD19 CAR negative control lentivirus.

The cell line can be used as negative control for the Anti-CD19 CAR/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1-BB-CD3ζ) (BPS Bioscience #79853).

Figure 1: Lenti-vector used to generate anti-CD19 CAR negative control lentivirus.

Figure 2. Schematic of anti-CD19 CAR negative control.
The anti-CD19 (scFv) is linked to the CD28 transmembrane motif.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
联系方式 二维码

服务热线

13829799985

关注公众号